Reference:	FOI.21592.26
Subject:	Intra-vitreal injections or implants
Date of Request:	14 September 2026

Requested:

1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2026:
   - Aflibercept – Eylea only (Any strength: 2mg or 8mg)
   - Aflibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution)
   - Aflibercept - Biosimilar (any brand other than Eylea)
   - Bevacizumab
   - Brolucizumab
   - Dexamethasone
   - Faricimab
   - Fluocinolone acetonide
   - Ranibizumab - including all Biosimilars

*If Eylea cannot be split by 2mg or 8mg strength, please provide the total number of injections/implants of Eylea

2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2026:

Please note, if a patient has received multiple injection/implants in the time period specified of May to August 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two

- Aflibercept – Eylea only (Any strength: 2mg or 8mg)
- Aflibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution)
- Aflibercept - Biosimilar (any brand other than Eylea)
- Bevacizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - including all Biosimilars

*If Eylea cannot be split by 2mg or 8mg strength, please provide the total number of injections/implants of Eylea used for each indication

	Eye Conditions			
Treatment	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)	Non-infectious Uveitis (NIU)
Aflibercept – Eylea only (Any strength: 2mg or 8mg)				n/a

Aflibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution)				n/a
Aflibercept - Biosimilar (any brand other than Eylea)				n/a
Bevacizumab				n/a
Dexamethasone				
Faricimab				n/a
Fluocinolone acetonide				

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number (less than 5) and have therefore, replaced the figures in the tables with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table overleaf, the number of each of the listed intravitreal injections/implants administered, during the period 1 May to 31 August 2026.

Medication	Number
Aflibercept – Eylea only (Any strength: 2mg or 8mg)	725
Aflibercept – Eylea 8mg only	219
Aflibercept - Biosimilar (any brand other than Eylea)	0
Bevacizumab	0
Brolucizumab	0
Dexamethasone (Ozurdex)	67
Faricimab	1,666
Fluocinolone acetonide	*
Ranibizumab - including all Biosimilars	1,566

2. The UHB provides within the table below, the number of each of the listed intravitreal injections/implants administered, by eye condition, during the period 1 May to 31 August 2026.

	Eye Conditions			
Treatment	**Wet Age-Related Macular Degeneration (wAMD)**	**Diabetic Macular Oedema (DMO)**	**Retinal Vein Occlusion (RVO)**	**Non-infectious Uveitis (NIU)**
Aflibercept – Eylea only (Any strength: 2mg or 8mg)	415	127	140	0

Aflibercept – Eylea 8mg only	153	21	64	0
Aflibercept - Biosimilar (any brand other than Eylea)	0	0	0	0
Bevacizumab	0	0	0	0
Dexamethasone	0	38	29	0
Faricimab	1,097	208	159	0
Fluocinolone acetonide	0	*	0	0